Kestra Medical Technologies, LTD Form 4 insider transactions

Kestra Medical Technologies' General Counsel and Chief Administrative Officer, Traci S. Umberger, sold 10,500 common shares for a weighted average price of $26.6858 per share under a pre-arranged 10b5-1 trading plan.

Kestra Medical Technologies CEO Brian Daniel Webster sold 15,000 common shares for a weighted average price of $26.5898, executed under a pre-arranged 10b5-1 trading plan.

Kestra Medical Technologies' Chief Business Officer, Timothy P. Moran, was granted 19,557 restricted stock units.

Kestra Medical Technologies' CCO, Alfred J. Ford Jr., amended a filing to report a previously omitted purchase of 20,000 common shares at $17 each from the IPO reserved share program.

Kestra Medical Technologies' General Counsel, Traci S. Umberger, amended a filing to disclose the purchase of 13,500 common shares at $17 each from the IPO reserved share program.

Kestra Medical Technologies Director Mary Kay Ladone reported an acquisition of 10,909 restricted stock units, increasing her beneficial ownership to 23,903 common shares.

Kestra Medical Technologies Director Raymond W. Cohen increased his direct ownership through a purchase and a restricted stock unit grant, correcting a prior filing omission.

Kestra Medical Technologies Director Conor Hanley was granted 13,120 restricted stock units, vesting in 2026.

Kestra Medical Technologies Director and 10% owner, Jeffrey Lawrence Schwartz, acquired 10,909 restricted stock units vesting in September 2026.

Kestra Medical Technologies Director Elizabeth Kwo was granted 10,909 restricted stock units, vesting in September 2026.

Kestra Medical Technologies Director Raymond Cohen reported the vesting of 4,331 restricted common shares, part of a larger grant converted from partnership units during the company's initial public offering.

Kestra Medical Technologies' President and CEO, Brian Daniel Webster, was granted 88,235 restricted stock units and holds 1.78 million options, aligning his interests with long-term shareholder value.

Kestra Medical Technologies' Chief Financial Officer, Vaseem Mahboob, was granted 22,059 restricted stock units and holds 159,000 stock options, aligning executive incentives with long-term company performance.

Traci S. Umberger, General Counsel and Chief Administrative Officer of Kestra Medical Technologies, Ltd., was granted 29,412 restricted stock units and holds 541,000 stock options, aligning executive incentives with long-term company performance.

Kestra Medical Technologies, Ltd. has granted 29,412 restricted stock units and 118,000 stock options to Chief Commercial Officer Alfred J. Ford Jr. as part of his compensation package.